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variety of organisms from bacteria to plants to humans [1, 
2]. It catalyzes the reaction steps from hypoxanthine to 
xanthine and from xanthine to uric acid in the pathway of 
purine metabolism (Fig. 1); some aldehydes are also good 
substrates. The enzyme was first isolated from cow’s milk 
as aldehyde oxidase in 1902 [3], and was subsequently 
shown [4] to be the same as the enzyme previously iden-
tified as xanthine oxidase in milk [5]. XOR contains a 
molybdenum cofactor (Moco; molybdopterin), two non-
identical [2Fe–2S] clusters, and one FAD per subunit of the 
dimeric protein, which has a total molecular weight (MW) 
of about 300 kDa. This enzyme is the best-studied complex 
flavoprotein, and several reviews are available [1, 2, 6–15].
In primates or uricoteric animals, uric acid is the end 
product of purine catabolism and is formed in cytosol 
[16]. However, in other organisms, e.g., in mammalians 
other than primates, uric acid is further oxidized to allan-
toin by uricase in peroxisomes [17–19]. Humans have lost 
uricase during evolution [20], and secrete uric acid mainly 
via kidney and partially via intestine. In kidney, uric acid 
is recovered via nephron transporter URAT1 [21] and also 
via ABCG2 transporter [22–24]. ABCG2 also mediates 
uric acid secretion from intestine, and a defect of this activ-
ity is one of the reasons for hyperuricemia [25]. A blood 
uric acid concentration higher than 7 mg/dL is a risk fac-
tor for gout [26] and is also proposed to be an independent 
risk factor for various diseases related to so-called meta-
bolic syndrome [27], as well as kidney diseases [28] and 
endothelial dysfunction [29–32]. In order to decrease the 
concentration of uric acid in blood, drugs that inhibit bio-
synthesis or increase secretion of uric acid have been used 
clinically [33]. The XOR inhibitor allopurinol, an isomer 
of hypoxanthine, has been used to treat gout for more than 
40 years, and the efficacy of XOR inhibition as a strategy 
for prevention of gout attack is well established. However, 
Abstract Xanthine oxidoreductase (XOR), which is 
widely distributed from humans to bacteria, has a key role 
in purine catabolism, catalyzing two steps of sequential 
hydroxylation from hypoxanthine to xanthine and from 
xanthine to urate at its molybdenum cofactor (Moco). 
Human XOR is considered to be a target of drugs not only 
for therapy of hyperuricemia and gout, but also potentially 
for a wide variety of other diseases. In this review, we focus 
on studies of XOR inhibitors and their implications for 
understanding the chemical nature and reaction mechanism 
of the Moco active site of XOR. We also discuss further 
experimental or clinical studies that would be helpful to 
clarify remaining issues.
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Introduction
Xanthine oxidoreductase (XOR), which can act as a xan-
thine oxidase or xanthine dehydrogenase, exists in a wide 
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in some cases allopurinol causes serious adverse effects 
[34, 35], and so new inhibitors of uric acid formation have 
been sought to replace it in such cases. Indeed, a patent 
survey indicated that more than 250 XOR inhibitors have 
been investigated as candidate drugs [36]. However, none 
of them, other than allopurinol, has been approved until 
quite recently: febuxostat was approved in EU countries 
in 2008, in the USA in 2009, and subsequently in various 
other countries including Japan (2011). Another inhibi-
tor, topiroxostat, has also been approved recently in Japan 
(2013). In this paper, we review the implications of enzy-
mological and developmental studies of XOR inhibitors for 
understanding the chemical nature and reaction mechanism 
of the Moco active site of XOR.
Brief overview of XOR
Mammalian XOR exists as a homodimer of 150 kDa 
subunits; its three-dimensional and primary structures are 
illustrated in Fig. 2. Each of the subunits is composed of 
three domains. The largest, C-terminal domain contains the 
molybdenum cofactor (Moco), the intermediate domain 
contains flavin adenine dinucleotide (FAD) cofactor and 
the smallest, N-terminal domain contains the two iron sul-
fur clusters ([2Fe–2S] type). The redox reaction centers 
are positioned in the order of Moco, the two iron clusters 
and FAD with an overall separation of less than 14 Å, as is 
usually the case for electron transfer components [37–41]. 
The iron sulfur clusters are designated Fe/S I and Fe/S II 
[42–45]; Fe/S II has the higher redox potential, and shows 
unusually broad EPR signals at temperatures below 22 K, 
whereas Fe/S I is typical plant ferredoxin-type center [44]. 
Assignment of these clusters in the primary structure was 
performed by means of site-directed mutagenesis studies 
[43]. The hydroxylation reaction of purine takes place at 
Moco; firstly, two electrons are transferred from the sub-
strate to Mo of Moco, reducing Mo(VI) to Mo(IV); Mo(V) 
is observed only transiently. It is considered that H+ + 2e− 
derived from the substrate, in the form of hydride (H−, 
i.e., a hydrogen atom with two electrons) is transferred to 
a sulfur ligand of Moco (Mo(VI) = S → Mo(IV)–SH) [1, 
46, 47]. The Mo(V) species is not formed by one-electron 
transfer from the substrate, but rather is formed during 
the process of electron transfer from Mo to the iron sulfur 
center. Electrons are transferred to FAD via the iron sulfur 
centers in the order illustrated in Fig. 2. Finally, NAD+ or 
oxygen molecule receives an electron from FAD to afford 
NADH or H2O2 and O2−, respectively. XOR from most 
organisms uses NAD+ as an electron acceptor and is called 
xanthine dehydrogenase (XDH), while XOR proteins from 
mammals can be converted to the oxidase form (XO), 
which uses exclusively the oxygen molecule as an electron 
acceptor [48–52]. The conversion involves posttranslational 
modification such as disulfide formation or proteolytic 
nicking of the same XOR gene product [2, 53–55]. Histori-
cally, XOR was isolated from cow’s milk after irreversible 
conversion to XO by nicking the enzyme with pancreatin 
to isolate it from milk fat globule membrane [56], so the 
enzyme has been called ‘xanthine oxidase’, but it is consid-
ered that the enzyme actually exists in xanthine dehydro-
genase form [48, 57]. The physiological and pathological 
Fig. 1  Schematic illustra-
tion of purine metabolism in 
primates. Hypoxanthine formed 
from inosine is hydroxylated 
to afford xanthine. Xanthine is 
also formed from guanine by 
deamination. Xanthine is further 
hydroxylated to uric acid (the 
final product in primates) in 
cytosol. Uric acid is converted 
to allantoin in peroxisomes of 
other mammalian species
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roles of the conversion have long attracted attention, par-
ticularly from researchers in the medical field, but remain 
controversial [6, 12, 14, 58], although the mechanism of 
the conversion is well understood and has been reviewed in 
detail [10].
Inhibitor characteristics and inhibitory mechanism
Allopurinol
Allopurinol (4-OH-pyrazolo-pyrimidine) has been used as 
an anti-gout drug for over 40 years. It was synthesized by 
Robins [59] and introduced into clinical use by Elion et al. 
[60]. It is an isomer of hypoxanthine, and was initially 
reported to be a simple competitive inhibitor that binds to the 
molybdenum center competitively with respect to xanthine, 
with the Ki value of 7 × 10−7 M for the rat enzyme and 
1.9 × 10−7 M for the human enzyme [61]. The IC50 value 
was reported as 1,700 nM [36]. However, it subsequently 
became clear that the inhibitory mechanism of allopuri-
nol is more complicated and potent than initially envisaged 
[62, 63]. Massey et al. [63] showed that the inhibition pro-
gresses in a time-dependent manner, with eventual formation 
of a tightly bound complex of the reduced enzyme (MoIV) 
with oxipurinol (often called alloxanthine) generated by 
hydroxylation of allopurinol, as illustrated in Fig. 3A. The 
reason for the time dependence of the inhibition is the time 
taken to convert allopurinol to oxipurinol and to trap reduced 
MoIV that is transiently formed during enzymatic turnover. 
The oxipurinol–molybdenum complex dissociates upon re-
oxidation of Mo(IV) in air (t1/2 = 300 min at 25 °C) due 
to electron transfer to oxidized cofactors [63, 64]. Massey 
et al. [63] also concluded that the naturally isolated enzyme 
contained a significant amount of inactive form that could 
not bind oxipurinol, since the molar ratio of oxipurinol per 
enzyme FAD was less than one, and was correlated linearly 
to the specific activity of various enzyme samples. They 
found subsequently that the inactive form is identical to the 
inactive enzyme generated by treatment with KCN, which 
releases a sulfur atom at the active site that is essential for 
catalytic activity. They also found that the inactive enzyme 
could be reactivated to the active sulfo form by Na235S treat-
ment, with incorporation of a stoichiometric amount of 35S 
into the enzyme [65, 66]. Thus, studies on the XOR inhibi-
tor allopurinol yielded the important finding that the sulfide 
ligand is essential for enzymatic activity. It was subsequently 
shown that sulfide is one of the coordinating ligands of the 
Mo atom [67]. Separation of the active and inactive forms of 
the enzyme was attempted by Edmondson et al. [68] using 
an affinity-gel-linked allopurinol analog with a long-chain 
ligand at the 5-position. On the other hand, Nishino et al. [69, 
70] used allopurinol in a rather different way: they applied 
the Mo(IV)–oxipurinol enzyme complex to folate affinity 
gel, which binds the free active site of any enzyme species, 
including the inactive desulfo form, and then they reactivated 
the passed-through fraction of Mo(IV)–oxipurinol complex 
by oxidation with ferricyanide. Thus, studies using allopu-
rinol provided important information about the presence of 
the inactive desulfo form in the naturally isolated enzyme 
Fig. 2  Structure of bovine 
XOR. Top Primary structure of 
bovine XOR subunit illustrated 
as three domains connected 
with two linker peptides. The 
N-terminal (red), the C-terminal 
(blue) and the intermediate  
(yellow) domains contain 
the iron–sulfur centers, the 
Moco center and the FAD 
center, respectively. Middle 
left Homodimer structure of 
bovine XOR illustrated with 
one subunit as a ribbon model 
and the other as a space-filling 
model. Right Cofactor arrange-
ment. Figures were generated 
from PDB ID 1F4Q. Bottom 
Hydroxylation reactions of 
hypoxanthine to xanthine and 
xanthine to uric acid.  
Two electrons are transferred to 
the Mo atom of Moco
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Fig. 3  Inhibitors of XOR. A Mechanism of inhibition of XOR by 
allopurinol. Allopurinol is a good substrate of XOR and is converted 
to oxipurinol with concomitant reduction of Mo (VI) to Mo(IV). 
Mo(IV) is mainly re-oxidized via electron transfer to the other cofac-
tors in XOR. During turnover, Mo(IV) reacts with oxipurinol to form 
a tightly bound complex; its crystal structure is shown as an electron-
density map. B Representative potent inhibitors reported after the 
clinical application of allopurinol. (a) from ICN Pharma: IC50, 25 
nM; (b) from C. Silipo: IC50, 10 nM; (c) from E. Merck: IC50, 40 
nM; (d) from Eli Lilly: IC50, 13 nM. In box inhibitors that have been 
examined in detail, including crystal structure of the XOR-bound 
form. (e) BOF-4272; (f) febuxostat, TEI-6720; (g) pyranoxostat, 
Y-700; (h) topiroxostat, FYX-051
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and the action mechanism of allopurinol as a suicide inhib-
itor, as well as providing a basis for separation of inactive 
enzyme. Before discovery of the desulfo form, Bray et al. 
had reported that XO isolated from bovine milk contains an 
inactive demolybdo form in a small amount that depended 
on the season and the location where the cows had grazed. 
These results suggested that the content of demolybdo form 
depends on the nutritional status of cows [71]. Nishino et al. 
[69] also noted that XOR isolated from Japanese cows’ milk 
contains a very small amount of inactive demolybdo form 
that can be isolated by first folate affinity column chroma-
tography (passed-through fractions), as shown previously. 
Similar results were observed for American cows’ milk 
(unpublished observations). On the other hand, Harrison 
et al. [72, 73] reported that XOR isolated from human milk 
was mostly in demolybdo form. In contrast, however, Mori-
waki et al. [74] or Krenitsky et al. [75] reported purification 
and characterization of human liver enzyme and showed that 
its activity is not greatly different from that of normal bovine 
milk XOR. The content of inactive enzyme is an important 
issue in evaluating the effects of XOR inhibitors in vivo, 
since structure-based inhibitors can bind to inactive enzyme 
species, as described later, and this would decrease the effi-
cacy of drugs by lowering the free inhibitor concentration in 
blood.
Inhibitors other than allopurinol
Various inhibitors were reported after the introduction 
of allopurinol, but most of them have not been approved 
for clinical use. Potent inhibitors identified from a patent 
survey or reported in the literature [76–79] are shown in 
Fig. 3B, together with their IC50 values (inhibitor concen-
tration required to inhibit the enzyme activity by 50 %). 
Other new XOR inhibitors have also been reported in the 
last few years (structures not shown here) [80–92]. How-
ever, it should be pointed out that the IC50 values are not 
necessarily reliable. For example, as described in the previ-
ous section, allopurinol is a potent suicide inhibitor, so its 
potency cannot be shown in terms of IC50, i.e., inhibition 
is dependent upon incubation time, enzyme concentration 
and percent of active form of the enzyme. In most cases, 
detailed enzymological or pharmacological data for the 
inhibitors were not reported, except in the case of 2-phe-
nyl-4-methyl-1,3-selenazole-5-carboxylic acid (PMSC), 
for which Ki and Ki′ values were given, in addition to a 
docking study [89]. Here, in order to illustrate the utility 
of XOR inhibitor studies for understanding the chemi-
cal nature and reaction mechanism of the enzyme, we will 
focus on the inhibitors BOF-4272, TEI-6720, Y-700 and 
FYX-051, which were characterized in detail using fully 
active bovine XO after the mid-1980s (Fig. 3B in box). The 
last compound will be described in the next section.
BOF‑4272
Sodium-8-(3-methoxy-4-phenylsulfinylphenyl)pyraz
olo[1,5-a]-1,3,5-triazine-4-olate monohydrate (BOF-4272) 
is separable into the (−)-isomer and (+) isomer by HPLC 
using a Chiralcel OD column. The (−)-isomer showed 
much higher affinity for the enzyme, and steady-state kinet-
ics showed mixed-type inhibition with Ki = 1.2 × 10−9 M 
and Ki′ = 9 × 10−9 M for xanthine and oxygen as sub-
strates, whereas the (+)-isomer showed Ki = 3 × 10−7 M 
and Ki′ = 9 × 10−6 M [93]. A plausible explanation for 
the mixed-type inhibition is the difference of Ki for oxi-
dized and Ki′ for reduced enzyme [93], and this may also 
be the case for other inhibitors (Fig. 3B in box). Although 
BOF-4272 was a potent inhibitor in animal experiments 
[94], clinical studies indicated that its efficacy varies from 
individual to individual; in some cases it was as effective 
as allopurinol on a weight basis, but in others it was less 
effective. It was concluded that the drug concentration in 
blood was insufficient, probably due to hepatic metabo-
lism, as well as poor absorption of the drug from the intes-
tine. Overall, this work indicated that uric acid production 
in humans occurs not only in liver, but also to a significant 
extent in other organs, whereas other animals produce uric 
acid predominantly in liver. Thus, it may be necessary to 
use a more potent inhibitor (Ki value less than 10−9) and 
to achieve a higher concentration of inhibitor in blood to 
obtain clinical efficacy. The lessons learned during the 
work on BOF-4272 contributed greatly to the development 
of the following inhibitors as clinically useful drugs.
Febuxostat (TEI‑6720; (2‑[3‑cyano‑4‑isobutoxyphenyl]‑ 
4‑methyl‑5‑thiazolecarboxylic acid) [105] and pyranostat  
(Y‑700; 1‑[3‑cyano‑4‑(2,2‑dimethylpropoxy)phenyl]‑ 
1H‑pyrazole‑4‑carboxylic acid)
These compounds were synthesized and selected by Kondo 
et al. [95] and Fukunari et al. [96] at Teijin Co. and Mit-
subishi Pharma Co., respectively, from among various syn-
thesized compounds based on the criteria of Ki value less 
than 10−9 M using fully active enzyme and good solubility. 
Both of them showed mixed-type inhibition in steady-state 
kinetic studies using fully active enzyme, like BOF-4272. 
It should be noted that inhibition of XOR by febuxostat is 
not linear with time [95], so steady-state analysis based on 
initial velocity was employed. The Kd value of XOR-febux-
ostat was too low to measure, even with a sensitive flores-
cence detection method. Based on the crystal structure and 
MD simulation, it was proposed that the protein structure 
around the Moco cavity has a dynamic open structure in 
solution, but adopts a more compact structure after binding 
of the inhibitor in the protein cavity [97]. This idea is con-
sistent with the fact that we have succeeded in crystallizing 
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many mammalian XOR proteins, including mutants, only 
in the presence of additional compounds such as inhibitors. 
XOR in which the Moco cavity is unoccupied has never 
been crystallized.
Crystal structures of XOR bound with salicylate, 
oxipurinol, BOF‑4272, febuxostat, and pyranostat
Salicylate
The crystal structure of bovine XOR was first determined 
as the salicylate-bound form (Fig. 4A) [37]. Salicylate, a 
weak competitive inhibitor, is normally included during 
purification to prevent conversion of sulfo-XOR to inac-
tive desulfo-XOR. In the XDH crystal structure, the salicy-
late molecule is bound 6.5 Å from the Mo ion, in a posi-
tion that would be overlapped by larger aromatic substrates 
(hypoxanthine or xanthine) present at the binding site. 
Thus, although salicylate itself does not bind to the Moco, 
it blocks the approach of substrates to the metal complex. 
Salicylate binding is mediated by several hydrogen bonds 
and electrostatic interactions. The inhibitor is aligned paral-
lel to the phenyl ring of Phe 914, but the two aromatic rings 
only slightly overlap. At the same time, the phenyl ring of 
Phe 1009 interacts edge-on with the center of the salicylate 
ring. Both of the carboxylate atoms are close to the guan-
idinium group of Arg 880 and they also interact with the 
hydroxyl side chain of Thr 1010 and via a water molecule 
with the carboxylate of Glu 1261. The salicylate hydroxyl 
group forms hydrogen bonds to both the backbone amide 
and hydroxyl side chain of Thr 1010.
Oxipurinol (Allopurinol)
The crystal structure of the complex of pre-reduced fully 
active bovine XO with oxipurinol was determined at 
2.0 Å resolution [98]. Strong electron density connected 
oxipurinol and the Mo atom (Fig. 3A). The N2 nitrogen of 
oxipurinol replaces the equatorial hydroxyl ligand of the 
molybdenum atom, coordinating directly to the metal atom 
at a distance of 2.3 Å with a 180° angle between Mo-ion, 
N2-atom and the pyrazole ring (Figs. 3A, 4A). The other 
position is occupied by the –SH atom located at a dis-
tance of about 2.4 Å from the central metal ion, in accord-
ance with the previously described mechanism of inhibi-
tion by allopurinol. Oxipurinol forms hydrogen bonds 
with Glu802 via its 4-position (=O; corresponding to the 
6-position of xanthine), Arg880 via its 6-position (=O; 
corresponding to the 2-position of xanthine) and Glu1261 
via N1. These interactions provide clues to the binding 
mode of substrate xanthine, an isomer of oxipurinol, as 
will be discussed below.
BOF-4272, Febuxostat and pyranostat
The crystal structures of the complexes of milk XOR 
with BOF-4272, febuxostat and pyranostat show fea-
tures that account for the tight binding; these inhibitors fit 
well into the substrate-binding channel of XOR, and no 
Fig. 4  Crystal structures of potent inhibitors bound to the XOR 
Moco center. A Inhibitors and amino acid residues are illustrated 
by stick models with atom colors reproduced from PDB. Salicylate, 
PDB:1FO4; oxipurinol, PDB:3BDJ; BOF-4272: data deposition in 
process; Febuxostat, PDB:1N5X. B Schematic model of interaction 
of febuxostat with the active site cavity. Interaction of febustostat 
with the open cavity affords a weakly bound complex with the Ki val-
ues determined by steady-state kinetics using initial velocity, and this 
is subsequently converted to a tightly bound complex, of which the 
Kd value is too low to be determined accurately (see text)
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open space remains in the channel after binding of these 
compounds. Docking study of PMSC, which has higher 
potency than febuxostat, probably due to replacement of S 
by Se, suggested that PMSC may also fill the space in the 
same region, although the crystal structure was not avail-
able [80]. In contrast to oxipurinol, febuxostat and pyra-
nostat do not form a covalent bond with molybdenum. 
However, multiple weak interactions, such as ionic and 
hydrogen bonds, π–π interactions between the main five-
membered ring and nearby phenylalanine residues, van 
der Waals interactions, and hydrophobic interactions [95], 
result in tight binding; the dissociation constants are very 
low. Moreover, the fit of these compounds to the enzyme’s 
active-site structure is enhanced by rotation of the region 
between the five-membered ring and the benzene ring. 
Thus, these inhibitors efficiently match the structure of the 
substrate-binding region of the enzyme. A hydrogen-bond-
ing interaction of the CN group of the inhibitors with an 
asparagine residue of the enzyme should be noted. In the 
crystal structure, the side chain amide of Asn768 and the 
CN group at the 3-position are only ~3 Å apart [94, 96]. 
Although this asparagine residue is located too far from the 
active center for direct involvement in purine substrate rec-
ognition or catalytic activity, the CN group of these inhibi-
tors is necessary for potent enzyme inhibitory activity. A 
bulky hydrophobic moiety at the 4-position is also essential 
for tight binding. The 4-isobutoxy group is surrounded by 
hydrophobic amino acids at distances of around 4 Å [96]. 
Interestingly, these crystallographically determined fea-
tures of the inhibitor binding mode suggest that the fit of 
the inhibitors in the cavity is too tight to allow entry of the 
inhibitors into the cavity, as shown in Fig. 4B, suggesting 
that initially the inhibitors bind rather weakly to an open 
form of the dynamic protein structure. The Ki and Ki′ val-
ues determined by steady-state kinetics using initial rate 
would reflect this, while the Kd values for the subsequent 
tight interaction are too low to determine accurately. Inter-
estingly, these structure-based inhibitors do not efficiently 
inhibit bacterial XOR, even though its crystal structure is 
very similar and important amino acid residues involved 
in catalysis are conserved. MD simulation study indicated 
that the mobility of the active-site cavity is altered due to 
replacement of amino acid residues not involved in cataly-
sis, providing further evidence for the dynamic flexibility 
of Moco in the active site [97].
Topiroxostat: (FYX-051, 4-[5-Pyridin-4-yl-1H-[1, 2, 4] 
triazol-3-yl]pyridine-2-carbonitrile)
It is a potent inhibitor that serves as a suicide substrate 
of XOR [99, 100] and also has similar features to struc-
ture-based inhibitors such as febuxostat and pyranostat. 
Topiroxostat transfers two electrons to the enzyme, 
forming a stable complex with Mo(IV) within a short time 
[98]. In the crystal structure of the complex of fully active 
XDH and topiroxostat at 1.9 Å resolution (Fig. 5A, B), it 
was seen that one of the C atoms of topiroxostat, next to the 
N atom, forms a covalent bond with molybdenum through 
oxygen. The bridging electron density between the Mo and 
C atoms is bent at an angle of 152°, and spans 3.3 Å in total 
(Mo–O, 2.0 Å and O–C, 1.3 Å), indicating Mo–O–C bond 
formation. It had not been possible to identify definitively 
the chemical nature of atoms bound to the Mo atom based 
on electron density alone in the previous lower-resolution 
crystal structure with XDH that was not fully active [37], 
but three ligands of the Mo atom were tentatively assigned 
as =S, =O, and –OH according to the previously proposed 
geometry [101]. However, at higher resolution, with fully 
active XDH, the topiroxostat-inhibited XDH structure 
provided an updated geometry of the Mo ligands and the 
ligands were definitely assigned as =S (–SH in reduced 
Mo) and –O–C– at the equatorial position, and =O at the 
apical position from reduced Mo (IV), as shown in Fig. 5, 
by comparison with the structure of desulfo-XO bound 
with the same inhibitor (Fig. 5C, D). This updated geom-
etry is consistent with magnetic circular dichroism findings 
[102], X-ray absorption spectroscopy [103] and analysis of 
model compounds. Various interactions, including hydro-
gen bonding with surrounding amino acids, hydrophobic 
interaction and π–π stacking interaction with two phenyla-
lanines, were observed, similarly to the cases of febuxostat 
and pyranostat. Mo(IV)–O–C– of the initially formed com-
plex of Mo(IV)–topiroxostat decomposed with a half-life 
of approximately 20 h at 25 °C and formed another com-
plex interacting in different manner [100]. The structure of 
this complex provided important insight into the hydroxy-
lation mechanism. An identical structure was formed 
when dithionite-reduced Mo(IV) was mixed with hydroxy 
topiroxostat. It was shown that protonated Glu1261 forms 
a hydrogen bond with substrate nitrogen next to the carbon 
atom to be hydroxylated, suggesting an important role of 
protonated Glu1261, i.e., hydrogen bonding to the nitro-
gen atom facilitates nucleophilic attack on adjacent carbon 
by the basic oxygen atom (Mo–O–) [99]. This concept is 
consistent with the role of the side chain of a glutamic acid 
residue near the Mo–OH group in the reaction of aldehyde 
oxidoreductase (ALO) from the sulfate-reducing anaero-
bic bacterium Desulfovibrio gigas [101]. Thus, it can be 
expected that a C atom of various N-heterocyclic com-
pounds can be hydroxylated, if the compounds have affin-
ity for the active-site cavity. We believe that physiological 
substrates are also activated in essentially the same manner. 
When this glutamic acid residue was altered by mutagen-
esis to alanine, the activity was completely lost [104]. The 
rate-limiting step is cleavage of the Mo–O–C bond by a 
water molecule to give Mo–OH plus C–OH, but no such 
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water molecule was observed in the crystal structure of the 
topiroxostat–XOR complex, probably because the site is 
fully occupied by a bulky hydrophobic molecule [99].
Mechanism of hydroxylation of purine substrates
We previously reviewed the hydroxylation mechanism at 
the Moco site in this journal in 2008 [10]. As described 
then, two contradictory models have been proposed for 
the substrate-binding mode and activation mechanism. 
We revisit this issue here because, despite further research 
[105–108], the issue remains controversial [15, 106, 109]. 
The first model shown in Fig. 6A-a is based on site-directed 
studies [40], the binding mode of oxipurinol explored by 
X-ray structure analyses with R. capsulatus XDH [38] 
and with bovine XOR [98], and the mechanism in the case 
of topiroxostat [99]. Nucleophilic reaction is activated 
or facilitated through hydrogen bonds formed between 
the substrate and amino acid residues, particularly by 
Glu1261, as described in the section on topiroxostat. The 
same authors subsequently presented X-ray data at high 
resolution showing the binding mode of demolybdo-XOR 
and urate [105]. These binding modes are consistent with 
the metabolic sequence, i.e., hydroxylation at the 2-position 
of hypoxanthine precedes that at the 8-position. That is, 
interaction of the 2-position keto group (C=O) and Arg881 
is important for efficient hydroxylation at the 8-position, as 
discussed in connection with mutagenesis studies [10, 40]. 
The other mode does not have such an interaction. This is 
consistent with the report that mutation of the correspond-
ing arginine to glutamate in A. nidulans XOR resulted in 
loss of xanthine hydroxylation activity, though activity 
towards hypoxanthine still remained [110].
Another binding mode and activation mechanism were 
proposed by Hille et al. [111, 112] (Figure 6A-b), in which 
negative charge can be accumulated at the 6-position oxy-
gen through interaction with the positive charge of the 
guanidinium group of Arg880; this would be energetically 
more favorable. A classification scheme for bad (slow) 
(Fig. 6A-a) and good (fast) (Fig. 6A-b) substrates was pro-
posed based on their orientation in the active site, in the 
light of experimental data for 2-hydroxy-6-methylpurine 
as a substrate and for the xanthine-bound desulfo form 
Fig. 5  Crystal structure of topiroxostat (FYX-051) bound to XOR 
and binding modes of substrates. A Electron-density map around the 
Mo atom in the complex of fully active XOR with topiroxostat. B 
Interaction of amino acid residues in the protein cavity. Two proto-
nated glutamate residues, E802 and E1261, are at hydrogen-bonding 
distances from N atoms of topiroxostat. C Electron density around 
the Mo atom in the complex of fully active XOR with topiroxostat, 
showing electron density between Mo and a carbon atom of topirox-
ostat. See similar electron densities of two sulfur atoms connected to 
pterin moiety. D Electron density around the Mo atom in the case of 
inactive desulfo-XOR, showing no electron density between Mo and 
a carbon atom. Lower electron density is observed, similar to that 
another oxygen atom coordinated to the equatorial position. Both are 
viewed from the apical position. Differences in electron density are 
indicated by arrows
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of bovine XO. The former structure was considered to be 
a poor orientation, and therefore the reaction is slow due 
to high activation energy. However, the slower rate is not 
due to a slower rate of hydroxylation, but rather is due to a 
slower rate of release of the product [113].
Theoretical calculations using density-functional theory 
or more extensive QM/MM studies, however, supported 
the model shown in Fig. 6C-a [107, 114]. Since then, X-ray 
crystallographic studies of urate-bound demolybdo-XOR 
(Fig. 6C) and the urate-bound reduced Mo form (Fig. 6D) 
have been reported [105]. The occupancy was only around 
60 %, and the broad electron density suggests a mixture of 
sp3 and sp2 modes; the latter might be a reaction intermedi-
ate during the reaction of xanthine hydroxylation, since it 
is very unstable and can be obtained at high concentration 
of urate. Although Glu802 was proposed to promote tau-
tomerization of xanthine in the alternate binding mode, the 
water molecule located at 3N and 9N of xanthine (Fig. 6C, 
D), should serve to assist release of the urate product [13, 
114]. Figure 6B shows a hypoxanthine-bound desulfo form 
of XOR determined in our laboratory (to be published else-
where) that is quite different from the structure proposed 
by Cao et al. [106]. We have also examined the structures 
of a number of xanthine-bound desulfo-form XORs, but 
we have not obtained a clear and consistent electron den-
sity even at high resolution. We think the reason for this 
may be that the active-site cavity of the desulfo form can 
take a variety of structures for binding various substrates, 
indicating that X-ray structures of the desulfo form are 
not appropriate for discussing catalytically relevant bind-
ing modes of substrates. Subsequently, Hille et al. [15, 
106, 109] presented several critiques of the urate-binding 
mode [105] and they provided additional data derived from 
site-directed mutagenesis of the R. capsulatus enzyme fol-
lowed by kinetic studies after submission of this manu-
script [115]. However, those kinetic data obtained with the 
mutant enzyme can also be explained in terms of the alter-
native binding mode described by Metz and Thiel [108] 
and the bacterial XDH exhibits different molecular dynam-
ics around the active-site cavity from the bovine enzyme 
[97] that may influence the release kinetics. The focus of 
discussion has changed from the initial activation energy 
[112] to the release kinetics, and the issue of the substrate-
binding mode still requires clarification.
Metabolic and pharmacological effects of XOR 
inhibition
Possible metabolic and pathological roles of XOR are 
summarized schematically in Fig. 7. Metabolic effects 
of inhibition can generally be examined in experimental 
Fig. 6  Crystal structure of XOR with oxipurines. A Two bind-
ing models have been proposed. (a) Binding mode proposed by the 
authors of this paper. (b) Binding mode proposed by Hille et al. and 
Kisker et al. B Binding mode for the complex of desulfo-XOR with 
hypoxanthine obtained by the authors of this paper. C Crystal struc-
tures urate bound to demolybdo-XOR. D Urate bound to reduced Mo 
of fully active XOR
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animals or humans. However, higher animals other than 
primates convert uric acid to more soluble allantoin 
(Fig. 1), catalyzed by peroxisomal uricase; and inhibitors 
of uricase, such as oxonic acid, are used for experiments 
in model animals, such as mouse or rat. In these animals, 
xanthine is accumulated and secreted into urine via kid-
ney. However, hypoxanthine is less markedly accumulated, 
being mostly converted to IMP via hypoxanthine guanine 
phosphoribosyl transferase in the salvage pathway with 
consumption of phosphoribosyl pyrophosphate (PRPP) 
(Fig. 1). Accumulated ribonucleotides (AMP and GMP) 
inhibit the enzyme catalyzing the initial step of purine de 
novo synthesis, glutamine phosphoribosyl amidotrans-
ferase (GPATase) (Fig. 7), in an allosteric manner [116]. 
The combined effect of this feedback allosteric inhibi-
tion and consumption of PRPP might substantially reduce 
the size of the purine substrate pool, and this might be 
an effective strategy to treat hyperuricemia. On the other 
hand, most of the accumulated xanthine is secreted into 
urine. However, these animals do not seem to have toler-
ance for severe xanthinuria, which causes kidney dam-
age due to xanthine stone formation [117–120] and often 
leads to bladder cancer [121]. Urolithiasis is sometimes 
accompanied with xanthinuria due to xanthine deposi-
tion, and this may occasionally lead to acute renal fail-
ure [122–127]. On the other hand, human XOR-deficient 
patients, possible models for inhibition of XOR, do not 
have such severe symptoms except in the case of type III 
XOR deficiency, i.e., triple deficiency of XOR, aldehyde 
oxidase and sulfite oxidase, due to a defect in the synthe-
sis of Moco. Symptoms of Moco deficiency include severe 
neurological disorder, lens dislocation and dysmorphism, 
and the outcome is poor [128]. Type I xanthinuria is due 
to a genetic defect of XOR protein, and Type II, combined 
deficiency of XOR and AO, is due to a genetic defect of 
the enzyme catalyzing sulfide incorporation into Moco 
[129]. Thus, therapeutic usage of XOR inhibitors is not 
expected to have severe side effects if the inhibitor has 
no other effect than inhibition of XOR itself. However, it 
is still possible that patients with such genetic dysfunc-
tions may have compensatory system(s), since systematic 
genetic analysis has not been carried out in xanthinuria 
patients [130]. It was reported that XOR can convert nitrite 
to nitric oxide (NO) [131–135], a vasodilator, and XOR-
produced NO may have a protective role in myocardial 
ischemia [136, 137]. Thus, potent XOR inhibitors may 
be contra-indicated for patients having cardio-vascular 
disease. However, it should be noted that NO production 
by XO is very low even under anaerobic conditions, i.e., 
roughly ~1 % of urate formation activity from xanthine 
[50, 138]. Maia and Moura [135] reported NO forma-
tion by AO with aldehyde substrates. It is not surprising 
from a chemical point of view that the water-exchangeable 
hydroxyl group at OH–Mo(IV) can be replaced by NO2 to 
produce NO under strict anaerobic conditions, since vari-
ous compounds, such as urate, oxipurinol and FYX-051 
derivatives, can behave similarly. Nevertheless, although 
formation of NO is chemically feasible under strict anaer-
obic conditions, it is not yet clear whether these reactions 
have any physiological significance. Clinical studies of 
allopurinol, febuxostat and topiroxostat are due to start in 
EU countries [139].
Fig. 7  Schematic presenta-
tion of possible metabolic and 
pathological roles of XOR. ROS 
reactive oxygen species, NOS 
nitric oxide synthetase. ·OH 
can be produced under special 
conditions
205J Biol Inorg Chem (2015) 20:195–207 
1 3
As XOR has the potential to produce reactive oxygen 
species (ROS), inhibitors of XOR might be effective in 
treating XOR-associated diseases [140]. XOR exists as the 
XDH form, which does not produce ROS, under normal 
conditions in vivo, where NAD+ exists dominantly in cyto-
sol, because it can be isolated as the XDH form by very 
careful extraction procedures. Thus, production of ROS 
requires conversion of XOR to XO under conditions where 
disulfide formation or proteolysis can occur, and then XO 
must be secreted into the blood. The resulting XO produces 
H2O2, O2− and highly active hydroxyl radical. Further, O2− 
scavenges NO produced by nitric oxide synthetase, react-
ing with NO to give toxic peroxynitrite (Fig. 7). On the 
other hand, uric acid is known to be a good anti-oxidant 
[141, 142]. The potential clinical utility of XOR inhibitors 
still remains to be established, although there are number 
of reports regarding this issue [140]. Nevertheless, XOR 
inhibitors should be useful tools to examine the pathophys-
iological significance of ROS generation by XOR.
Finally, we should comment on the possible interaction 
of XOR inhibitors with aldehyde oxidases (AOXs), which 
are also members of the molybdo-flavoenzyme family and 
have various physiological roles [143, 144]. All AOXs are 
very similar to XOR in molecular weight, cofactor composi-
tion and three-dimensional structure [145], but key residues 
for catalytic activity are not completely conserved in the 
active-site cavity, except for the glutamate residue located 
near the Mo atom that is important for catalytic activity. 
As already noted, the active-site residues are important not 
only for substrate specificity [40, 146], but also for binding 
affinity of XOR inhibitors. Further, even highly potent XOR 
inhibitors cannot effectively inhibit bacterial XDH, although 
only minor amino acid differences are observed in the Moco 
domain structures that influence the molecular dynam-
ics around the active-site cavity [97]. Thus, we think it is 
unlikely that highly potent XOR inhibitors would interact 
with AOXs. Conversely, highly potent AOX inhibitors may 
not interact with XOR. Nevertheless, this issue deserves 
further study, although as described already it is known that 
patients with combined XO and AOX (type II xanthinu-
ria) deficiency due to loss of Moco sulfurase [129] do not 
exhibit any severe symptoms [130, 147].
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